Chemistry:EcPLA

From HandWiki

EcPLA, also known as N-ethyl-N-cyclopropyllysergamide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2][3] It is an isomer of LSZ and is closely related to other amide-substituted lysergamides like MiPLA.[2][1][4][3] The drug has been encountered as a novel designer drug.[3]

Use and effects

EcPLA produces psychedelic effects in humans.[3]

Interactions

Pharmacology

Pharmacodynamics

EcPLA has been found to interact with serotonin receptors and dopamine receptors, among other targets.[2] It is a potency agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.[2]

The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[2] It has about 40% of the potency of LSD in this regard.[2]

Pharmacokinetics

The in-vitro metabolism of EcPLA has been studied.[5]

Chemistry

Analogues

Analogues of EcPLA include MiPLA, LAMPA (MPLA), EPLA, EiPLA, ETFELA, and LSZ, among others.[4][2][1]

History

EcPLA was first described in the scientific literature by a team that included Adam Halberstadt, Alexander Stratford, Jason Wallach, and David E. Nichols in 2019.[2] It was developed by Lizard Labs. The drug was encountered online as a novel designer drug in around 2020 and became more widely available in early 2022.[3]

See also

References

  1. 1.0 1.1 1.2 "Analytical profile of N-ethyl-N-cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ)" (in en). Drug Testing and Analysis 12 (10): 1514–1521. 2020. doi:10.1002/dta.2911. ISSN 1942-7611. PMID 32803833. 
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 "Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)". Psychopharmacology 236 (2): 799–808. February 2019. doi:10.1007/s00213-018-5055-9. PMID 30298278. 
  3. 3.0 3.1 3.2 3.3 3.4 "ECPLA" (in ru). https://aipsin.com/newsubstance/831/. 
  4. 4.0 4.1 "A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies". Analyst 150 (2): 290–308. January 2025. doi:10.1039/d4an01361a. PMID 39636448. 
  5. "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures". Analytical and Bioanalytical Chemistry 411 (19): 4751–4763. July 2019. doi:10.1007/s00216-018-1558-9. PMID 30617391. http://researchonline.ljmu.ac.uk/id/eprint/9841/13/ABC-01967-2018_02_accepted.pdf.